doi: Ghusn, W., De la Rosa, A., Sacoto, D., et al
Discontinuation due to side effects ran at 7% in Phase 2 data, which is lower than Semaglutides 11% discontinuation rate despite Semaglutide having a higher reported nausea incidence at 44%
| Who should use creams
Semaglutide Launch Overview Semaglutide Launch Overview India Leads the First Wave, Brazil Gears Up The global semaglutide market is entering a new phase, following the first wave of generic launches in India and expanding soon into additional markets such as Brazil
Clinical studies reveal a nuanced picture: the SUSTAIN-6 trial involving over 3,000 patients found that semaglutide users experienced modest reductions in systolic blood pressure over time, largely attributed to weight loss rather than the drug directly lowering pressure
As such, its commonly used in pre-workout and male enhancement supplements